By Musa Kureshy, MSc, Business Development Manager, Global Pricing Innovations Opportunity Assessments are a vital step for in-licensing new pipeline products or making go/no-go decisions around the clinical development of early-stage assets. To be able to achieve a reliable opportunity assessment it requires…
Recently Spain’s medicines regulatory bodies announced the requirement of additional “economic evaluation” data for therapeutics positioning reports (IPTs) which is the equivalent of a Health Technology Assessment process in the country. This change is part of a revolution of the overall HTA process…
By Rangaraja Konar, MBA, Business Analyst, Global Pricing Innovations Joseph Biden has been elected as the 46th President of the United States of America. He was the vice president of the states during Obama’s administration. The healthcare sector might be up to face…
PFIZER AND BIONTECH HAVE PRODUCED BETTER THAN EXPECTED EFFICACY RESULTS BUT WILL AWAIT FOR SAFETY DATA BEFORE FILING LATER THIS MONTH. THE PHIII INTERIM ANALYSIS FINDS VACCINE 90% EFFECTIVE WITH EUA FILING EXPECTED LATE NOVEMBER. Pfizer and BioNTech have announced positive interim Phase…
Blogpost by Dimitra Sotou, MIHP, Client Solutions Lead, GPI Canada is due to adjust its international reference pricing (#IRP) basket of comparator countries come January, the 1st, 2021. The change was announced by the PMPRB in the final version of new guidelines; after five years…
Blogpost created by Dimitra S. Sotou, Client Solutions Lead, Pricing & Market Access As opposed to the rest of key EU payers focusing on cost containment strategies for 2021, the German umbrella payer group GKV-Spitzenverband (GKV-SV) has announced to be targeting a +4.6%…
The White House has blocked stricter Food and Drug Administration (FDA) guidelines for the emergency release of the coronavirus vaccine, that would have likely prevented its approval before next month’s presidential election. The new FDA guidelines were submitted for approval to the Office…
Spending Changes Recently the French government has published its Social Security Finance Bill 2021 (PLFSS 2021), which covers the annual review of their health and social security expenditure. With the impact of COVID-19 increasing there seems to be an ever-increasing cost cutting exercise…
By Dimitra S. Sotou, Senior Consultant It’s been quite long since the US administration has been contemplating on techniques and mechanisms to lower prescription medicine prices covered by #Medicare . Different ideas have been brought onto the table over the past year with…
By Musa Kureshy, Business Development Manager The impact of COVID-19 has been felt by every country and industry and the Netherlands was no exception. COVID-19 impactied drug manufacturing in China leading to it coming to a stand still and India implemented export restrictions…
News summarised by Dimitra S. Sotou, Sr. Consultant, Pricing & Market Access ”Sputnik V” On Tuesday, President Vladimir Putin, announced that Russia is the first nation in the world to grant approval to a coronavirus vaccine. The approval has been granted, despite the…
Find out how the notion of value based pricing methodologies are becoming more common place in pharmaceutical medicines pricing and how Indication-based pricing (IBP) has been proposed as a potential solution for any medicine that offers benefits across many different indications. In this…
By Dimitra Sotou, Senior Consultant The Background The Italian Government has recently introduced new pricing and reimbursement rules with the central aim of making therapeutic value of prime importance in the assessment of new medicinal products conducted by AIFA. News sources confirm that…
By Tom Brockbank, Senior Consultant, Pricing & Market Access Trump announced on Friday 24th July, a one-month ultimatum for drug manufacturers to offer alternative plans to reduce drug prices. This will provide manufacturers an alternative option to the stalled plan to reference drug…
By Tom Brockbank, Senior Consultant, Pricing & Market Access Germany’s major payer AOK announces discount agreements and drug manufacturer incentives to ensure a stable supply chain throughout the COVID-19 pandemic AOK has announced two-year discount agreements for 119 drugs and an obligation for…
Click HERE to Register At GPI, working daily with price and reimbursement data, we have seen a range of PMA trends across high unmet need areas such as orphan/rare diseases. Increasing pharma focus on rare diseases resulted in payers having to adapt their…
By Musa Kureshy, Business Development Manager & Tom Brockbank, Senior Consultant On Tuesday 16th of June, new research was published by scientists from Oxford University which showed that the use of Dexamethasone, a low-dose steroid treatment, on patients suffering from COVID-19 reduced deaths…
By Ines Dieringer, Associate Consultant at Global Pricing Innovations Belgium, the Netherlands, and Ireland are aiming to undertake a joint Health Technology Assessment (HTA) through the Beneluxa agreement of Zolgensma, Novartis’ gene therapy medication to treat spinal muscular atrophy (SMA)1. Zolgensma is a…
AUTHORS: Ataide J, Murch L, Sotou D, Barkauskaite E, Patel P Beginning of the week and Day 1 for ISPOR Virtual 2020 today – We are very excited to share more results from our extensive R&D work. The infographic below provides a summary of…
AUTHORS: Soumalevris A, Murch L, Sotou D, Barkauskaite E, Patel P Despite the worldwide impact due to COVID-19 pandemic, GPI continues to invest on extensive R&D work leading the way on how data can be leveraged to ensure our partners stay ahead of the…
By Nairuti Patel, Associate Consultant, Global Pricing Innovations Amidst the COVID-19 pandemic, EU countries (Estonia, Greece, Netherlands and Romania) requested an opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the conditions under which early access to remdesivir through compassionate…
By Ines Dieringer, Associate Consultant The COVID-19 crisis has altered the way in which vaccines and drugs are developed and approved. In the private sector, we see unprecedented partnerships arise, while the public sector has experienced a policy shift towards a system of…
By Dimitra Sotou, Senior Consultant, Pricing & Market Access Day 1 of official lockdown today, and increasingly more organizations around the globe are facing tighter operational restrictions due to the COVID-19 outbreak – Name it: day-to-day work, restricted travel, team meetings, cancelled conferences,…
We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…
Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…
Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…
At the end of 2019, important legislative changes took place in the United States that could impact the country’s pharmaceutical industry over the coming years. The U.S. House of Representatives has passed the Lower Drug Costs Now Act on 12th December 2019, setting…
By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…
Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…
By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…
Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…
Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…
London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…
In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…
Last week, the result of negotiations between pharma companies and China’s National Healthcare Security administration was revealed. 150 medicines were evaluated, and the outcome is as follows. Out of the 119 new medicines evaluated, 70 were accepted onto the National Reimbursement Drug List…
Preeti Patel, the CEO of GPI, was invited to the Good Growth Summit, an event designed to inspire and connect female entrepreneurs across the US and UK tech ecosystem. The Summit took part at the St James’s Palace and was hosted by Princess…
We are still full steam ahead here at Global Pricing Innovations as we approach the end of 2019! Due to our continued growth & expansion, we are still actively recruiting for the below list of roles: Pricing and Market Access Lead Europe and…
This week, GPI had the pleasure to be invited to the Silicon Valley Comes to the UK (SVC2UK) summit. SVC2UK is an annual tech conference that brings world-leading tech entrepreneurs and investors to the UK for a series of workshops, panel discussions and…
Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…
Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…
Make sure you get in touch with our Experts to find out how you can optimise your commercial potential through data analytics. For more info, contact preeti.patel@globalpricing.com
Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…
New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support. London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…
BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…
In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…
Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…
On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…
President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…
Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…
Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…
